Ascenion’s parent company, the LifeScience Foundation for the Promotion of Science and Research, has provided funding of nearly EUR 0.5 million for the Fr1da study at the Institute of Diabetes Research, Helmholtz Zentrum München.
Scientists and physicians hope to improve the screening and optimal treatment of type 1 diabetes in children. Using only a few drops of blood, a rapid test can diagnose the disease before symptoms occur. This allows the affected family to learn how to avoid critical metabolic imbalances in their child. In Germany alone, around 30,000 children are affected by the disease, a further 2,000 acquiring it each year. The trial is a cooperation project between several institutes and associations and is being supported by a number of sponsors. Apart from screening, the trial will also evaluate innovative approaches to diabetes therapy being developed at the Helmholtz Zentrum München.
(Annual Review 2015)